Stephen J Nicholls

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Atherosclerosis imaging in drug development
    Stephen J Nicholls
    Cleveland Clinic, Department of Cardiovascular Medicine, Mail Code JJ 65, 9500 Euclid Avenue, Cleveland OH, 44195, USA 1 216 444 2678 1 216 445 5769
    Expert Opin Drug Discov 2:1241-50. 2007
  2. ncbi Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk
    Stephen J Nicholls
    Cardiovascular Medicine and Cell Biology and the Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, OH 44195, USA
    Expert Rev Cardiovasc Ther 9:1383-90. 2011
  3. ncbi Evacetrapib
    Stephen J Nicholls
    Departments of Cardiovascular Medicine and Cell Biology and the Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Cardiol Rep 14:245-50. 2012
  4. ncbi Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes
    Stephen J Nicholls
    Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, OH 44195, USA
    Diab Vasc Dis Res 9:89-94. 2012
  5. ncbi The emerging role of plasma lipidomics in cardiovascular drug discovery
    Rishi Puri
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland, OH, USA
    Expert Opin Drug Discov 7:63-72. 2012
  6. ncbi ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies
    Stephen J Nicholls
    Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, USA
    Cardiovasc Drugs Ther 26:181-7. 2012
  7. ncbi Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial
    Stephen J Nicholls
    Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, OH 44195, USA
    Cardiovasc Drugs Ther 26:71-5. 2012
  8. ncbi Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 52:255-62. 2008
  9. ncbi Diabetic dyslipidemia: extending the target beyond LDL cholesterol
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Eur J Cardiovasc Prev Rehabil 17:S20-4. 2010
  10. ncbi Coronary artery calcification and changes in atheroma burden in response to established medical therapies
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:263-70. 2007

Detail Information

Publications93

  1. ncbi Atherosclerosis imaging in drug development
    Stephen J Nicholls
    Cleveland Clinic, Department of Cardiovascular Medicine, Mail Code JJ 65, 9500 Euclid Avenue, Cleveland OH, 44195, USA 1 216 444 2678 1 216 445 5769
    Expert Opin Drug Discov 2:1241-50. 2007
    ..The design and implementation of clinical trials that employ serial imaging of the arterial wall has become increasingly used in the development of new therapies to target atherosclerotic cardiovascular disease...
  2. ncbi Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk
    Stephen J Nicholls
    Cardiovascular Medicine and Cell Biology and the Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, OH 44195, USA
    Expert Rev Cardiovasc Ther 9:1383-90. 2011
    ..The clinical experience of rosuvastatin will be reviewed in this article...
  3. ncbi Evacetrapib
    Stephen J Nicholls
    Departments of Cardiovascular Medicine and Cell Biology and the Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Cardiol Rep 14:245-50. 2012
    ..The potential effects on cardiovascular outcomes remain to be determined...
  4. ncbi Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes
    Stephen J Nicholls
    Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, OH 44195, USA
    Diab Vasc Dis Res 9:89-94. 2012
    ..The findings of these studies and rationale for development of dual PPAR-α/γ agonists will be reviewed...
  5. ncbi The emerging role of plasma lipidomics in cardiovascular drug discovery
    Rishi Puri
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland, OH, USA
    Expert Opin Drug Discov 7:63-72. 2012
    ..Despite these challenges, lipidomics is likely to result in the reclassification of diseases from a molecular perspective and play a key role the eventuation of personalized medicine...
  6. ncbi ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies
    Stephen J Nicholls
    Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, USA
    Cardiovasc Drugs Ther 26:181-7. 2012
    ..The ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE, NCT01067820) study aims to evaluate the effect of RVX-208 on plaque burden...
  7. ncbi Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial
    Stephen J Nicholls
    Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, OH 44195, USA
    Cardiovasc Drugs Ther 26:71-5. 2012
    ....
  8. ncbi Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 52:255-62. 2008
    ..Our goal was to characterize coronary atherosclerosis progression and arterial remodeling in diabetic patients...
  9. ncbi Diabetic dyslipidemia: extending the target beyond LDL cholesterol
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Eur J Cardiovasc Prev Rehabil 17:S20-4. 2010
    ..The high prevalence of hypertriglyceridemia and low levels of high-density lipoprotein cholesterol in diabetes presents further targets for the development of new cardioprotective therapies...
  10. ncbi Coronary artery calcification and changes in atheroma burden in response to established medical therapies
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:263-70. 2007
    ..This study sought to determine the relationship between coronary calcification and plaque progression in response to established medical therapies...
  11. ncbi Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    JAMA 297:499-508. 2007
    ..However, no data exist describing the relationship between statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and disease progression...
  12. ncbi Exploring the natural history of atherosclerosis with intravascular ultrasound
    Stephen J Nicholls
    Cleveland Clinic, Department of Cardiovascular Medicine, Mail Code JJ65, 9500 Euclid Ave, Cleveland OH, USA
    Expert Rev Cardiovasc Ther 5:295-306. 2007
    ..This article will review the increasing role of imaging modalities in the assessment of atherosclerosis and factors that influence its natural history...
  13. ncbi Comparison of coronary atherosclerotic volume in patients with glomerular filtration rates < or = 60 versus > 60 ml/min/1.73 m(2): a meta-analysis of intravascular ultrasound studies
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 99:813-6. 2007
    ..In conclusion, findings suggest that the increased incidence of clinical events in patients with impaired renal function may result from factors other than atherosclerotic burden...
  14. ncbi Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 105:69-76. 2010
    ..Greater lipid goal achievement with increasing dose supports the use of high-dose statin therapy for more effective cardiovascular prevention...
  15. ncbi Atherosclerosis regression: is low-density lipoprotein or high-density lipoprotein the answer?
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Mail Code JJ 65, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Atheroscler Rep 9:266-73. 2007
    ..The current state of evidence defining the relative contribution of changes in plasma lipids on the tendency to plaque regression is reviewed...
  16. ncbi Rate of progression of coronary atherosclerotic plaque in women
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1546-51. 2007
    ....
  17. ncbi High-density lipoprotein and progression rate of atherosclerosis in intravascular ultrasound trials
    Stephen J Nicholls
    Departments of Cardiovascular Medicine and Cell Biology and the Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Am J Cardiol 104:16E-21E. 2009
    ..As a result, it is likely that atherosclerosis imaging will become an integral component of early clinical development of novel therapies that enhance the functionality of HDL...
  18. ncbi Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction
    Stephen J Nicholls
    Department of Cardiovascular Medicine and Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, 9500 Euclid Ave, NE 10, Cleveland, OH 44195, USA
    Circulation 116:2315-24. 2007
    ..It is unclear whether abnormalities of arginine and nitric oxide metabolism are related to hemodynamic dysfunction and mortality in patients with cardiogenic shock (CS) after acute myocardial infarction...
  19. ncbi High-density lipoprotein and atheroma monitoring
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Curr Opin Cardiol 23:386-92. 2008
    ..To highlight the use of arterial wall imaging to evaluate the impact of therapies that promote high-density lipoproteins...
  20. ncbi Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosi
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Circulation 118:2506-14. 2008
    ..We investigated the relationship between lipid changes and progression of coronary atherosclerosis...
  21. ncbi New targets of high-density lipoprotein therapy
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Curr Opin Lipidol 18:421-6. 2007
    ..Currently available therapies raise levels of HDL-cholesterol by relatively modest amounts. This review describes experimental strategies that promote HDL activity...
  22. ncbi HDL: still a target for new therapies?
    Stephen J Nicholls
    Cleveland Clinic, Department of Cardiovascular Medicine, Heart and Vascular Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Opin Investig Drugs 9:950-6. 2008
    ..The evidence for the biological activity of HDL, and both existing and emerging therapeutic strategies are reviewed...
  23. ncbi Rosuvastatin and progression of atherosclerosis
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Expert Rev Cardiovasc Ther 6:925-33. 2008
    ..The impact of modifying levels of atherogenic lipids, HDL and markers of inflammation will be reviewed...
  24. ncbi Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Opin Lipidol 20:491-6. 2009
    ..To highlight clinical trials that have employed coronary artery imaging to evaluate the impact of medical therapies that target established cardiovascular risk factors...
  25. ncbi Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial
    Stephen J Nicholls
    Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, OH 44195, USA
    JAMA 306:2099-109. 2011
    ..Interest remains high in cholesteryl ester transfer protein (CETP) inhibitors as cardioprotective agents. Few studies have documented the efficacy and safety of CETP inhibitors in combination with commonly used statins...
  26. ncbi Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA
    Clin Chem 57:1762-70. 2011
    ..Although myeloperoxidase (MPO) monitoring is predictive for cardiovascular outcomes in suspected acute coronary syndromes, the value of serial testing is unknown...
  27. ncbi Apo a-I modulating therapies
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Curr Cardiol Rep 13:537-43. 2011
    ..As a result intensive efforts are in progress to develop new agents that promote HDL activity. Among these different approaches, a range of strategies that target apolipoprotein A-I, the major protein carried on HDL, are being evaluated...
  28. ncbi ETC-216 for coronary artery disease
    Stephen J Nicholls
    Heart and Vascular Institute, Cleveland Clinic, Department of Cardiovascular Medicine, Cleveland, OH 44195, USA
    Expert Opin Biol Ther 11:387-94. 2011
    ....
  29. ncbi Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 57:1111-9. 2011
    ..The purpose of this study was to investigate the safety, tolerability, and efficacy of RVX-208, the first oral agent designed to enhance apolipoprotein (apo) A-I synthesis...
  30. ncbi Is niacin ineffective? Or did AIM-HIGH miss its target?
    Stephen J Nicholls
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, USA
    Cleve Clin J Med 79:38-43. 2012
    ..But questions remain about this complex trial, which included intensive statin therapy in the active-treatment group and the control group...
  31. ncbi Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 57:153-9. 2011
    ..The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on atheroma progression...
  32. ncbi Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 55:2399-407. 2010
    ..The aim of this study was to investigate the relationship between intravascular ultrasound (IVUS)-derived measures of atherosclerosis and cardiovascular outcomes...
  33. ncbi Lessons from coronary intravascular ultrasound on the importance of raising high-density lipoprotein cholesterol
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Mail Code JJ 65, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Atheroscler Rep 12:301-7. 2010
    ..The relationship between high-density lipoprotein and progression of atherosclerosis and its implications for clinical practice are reviewed here...
  34. ncbi Emerging role of intravascular ultrasound in the assessment of experimental anti-atherosclerotic therapies
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland OH 44195, USA
    Curr Med Chem 13:1727-34. 2006
    ....
  35. ncbi Intravascular ultrasound in cardiovascular medicine
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Mail Code JJ65, 9500 Euclid Ave, Cleveland, Ohio 44195, USA
    Circulation 114:e55-9. 2006
  36. ncbi Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA
    J Lipid Res 51:3055-61. 2010
    ..This supports the need to intensify lipid management in patients with elevated Lp(a) levels...
  37. ncbi Effect of two intensive statin regimens on progression of coronary disease
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 365:2078-87. 2011
    ..However, few studies have either assessed the ability of intensive statin treatments to achieve disease regression or compared alternative approaches to maximal statin administration...
  38. ncbi Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study)
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 97:1553-7. 2006
    ..These results highlight the need for aggressive risk factor modification and a decrease in vascular inflammation in obese patients...
  39. ncbi Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials
    Ozgur Bayturan
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    JACC Cardiovasc Interv 2:672-8. 2009
    ..We investigated attenuated plaque (hypoechoic plaque with deep ultrasonic attenuation despite absence of bright calcium) in nonculprit lesions...
  40. ncbi Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial
    Paul Schoenhagen
    FAHA, Department of Cardiovascular Medicine, Cardiovascular Imaging, The Cleveland Clinic Foundation, HB 6, 9500 Euclid Ave, Cleveland OH 44195, USA
    Circulation 113:2826-34. 2006
    ..However, the remodeling response during plaque-stabilizing therapy and its relationship to markers of lipid metabolism and inflammation are incompletely understood...
  41. ncbi The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis
    Ozgur Bayturan
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, OH 44195, USA
    Arch Intern Med 170:478-84. 2010
    ..We sought to investigate the association of MetS and its component risk factors with progression of coronary atherosclerosis...
  42. ncbi Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound
    Stephen J Nicholls
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 47:1967-75. 2006
    ..Many risk factors did not predict angiographic disease severity, suggesting different mechanisms drive stenosis development and atheroma accumulation...
  43. ncbi Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study
    Stephen J Nicholls
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:67-74. 2006
    ..In this study, IVUS will be used to assess whether ACAT inhibition modifies progression of atherosclerotic plaque...
  44. ncbi Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial
    Ilke Sipahi
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Atherosclerosis 189:229-35. 2006
    ..Measurement of changes in lumen size may not be an accurate method to study progression and regression of atherosclerotic lesions with <50% stenosis...
  45. ncbi Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol
    Ozgur Bayturan
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 55:2736-42. 2010
    ..The purpose of this study was to characterize the determinants of plaque progression despite achieving very low levels of low-density lipoprotein cholesterol (LDL-C)...
  46. ncbi Plaque progression in coronary arteries with minimal luminal obstruction in intravascular ultrasound atherosclerosis trials
    Andrea J Lavoie
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 105:1679-83. 2010
    ..These minimally diseased arteries demonstrated evidence of vessel and luminal constriction, regardless of the angiographic appearance...
  47. ncbi Comparison of rates of progression of coronary atherosclerosis in patients with diabetes mellitus versus those with the metabolic syndrome
    Ozgur Bayturan
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 105:1735-9. 2010
    ..This finding highlights the deleterious effects of DM on the arterial wall independent of its associated metabolic abnormalities...
  48. ncbi Effect of torcetrapib on the progression of coronary atherosclerosis
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 356:1304-16. 2007
    ..Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, increases HDL cholesterol levels, but the functional effects associated with this mechanism remain uncertain...
  49. ncbi Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN)
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA
    Curr Med Res Opin 27:1119-29. 2011
    ..The Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN (SATURN, NCT00620542) aims to compare the effects of high-dose atorvastatin and rosuvastatin on disease progression...
  50. ncbi Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 297:1362-73. 2007
    ..Fibrates are weak agonists of peroxisome proliferator-activated receptor alpha (PPAR-alpha). No trials have reported effects of more potent and selective agents...
  51. ncbi Effect of ACAT inhibition on the progression of coronary atherosclerosis
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:1253-63. 2006
    ..The enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT) esterifies cholesterol in a variety of tissues. In some animal models, ACAT inhibitors have antiatherosclerotic effects...
  52. ncbi Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study)
    Stephen J Nicholls
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 96:1636-9. 2005
    ..These results suggest that intensive lipid lowering can have a dramatic effect on atheroma-prone regions and that remodeling in response to changes in plaque is a heterogenous process...
  53. ncbi Protein carbamylation links inflammation, smoking, uremia and atherogenesis
    Zeneng Wang
    Department of Cell Biology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Nat Med 13:1176-84. 2007
    ..We propose that protein carbamylation is a mechanism linking inflammation, smoking, uremia and coronary artery disease pathogenesis...
  54. ncbi Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease
    W H Wilson Tang
    Center for Cardiovascular Diagnostics and Prevention, Department of Cell Biology, Cleveland Clinic, Cleveland, OH 44195, USA
    Clin Chem 57:33-9. 2011
    ..Myeloperoxidase (MPO) concentrations predict adverse clinical outcomes in the setting of acute coronary syndromes and heart failure, but the prognostic role of MPO in stable patients with known atherosclerotic burden is unclear...
  55. ncbi Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials
    Ilke Sipahi
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Ann Intern Med 147:10-8. 2007
    ..However, whether a direct influence of beta-blockers on coronary atherosclerosis contributes to reduced recurrent myocardial infarction and total mortality rates is not known...
  56. ncbi Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano
    Stephen J Nicholls
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 47:992-7. 2006
    ..After infusion of rHDL containing AIM, regression of coronary atherosclerosis is accompanied by reverse remodeling of the EEM, resulting in no change in luminal dimensions...
  57. ncbi Static and serial assessments of coronary arterial remodeling are discordant: an intravascular ultrasound analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial
    Ilke Sipahi
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:544-50. 2006
    ..This is due to concomitant remodeling of the reference sites used in the static assessment. Intravascular ultrasound performed at a single point in time does not reflect the dynamic remodeling response...
  58. ncbi Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 299:1561-73. 2008
    ..Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers...
  59. ncbi Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 295:1556-65. 2006
    ....
  60. ncbi Coronary atherosclerosis can regress with very intensive statin therapy
    Ilke Sipahi
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 73:937-44. 2006
    ....
  61. ncbi Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis
    Ilke Sipahi
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 48:833-8. 2006
    ..e., systolic BP <120 mm Hg and diastolic BP <80 mm Hg). This study suggests that in patients with coronary artery disease, the optimal BP goal may be substantially lower than the <140/90 mm Hg level...
  62. ncbi Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis
    Adnan K Chhatriwalla
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 53:1110-5. 2009
    ..We investigated coronary atheroma progression in patients with low levels of low-density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP)...
  63. ncbi Compensatory enlargement of human coronary arteries during progression of atherosclerosis is unrelated to atheroma burden: serial intravascular ultrasound observations from the REVERSAL trial
    Ilke Sipahi
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA
    Eur Heart J 27:1664-70. 2006
    ..Atheroma burden is not a determinant of arterial enlargement during the progression of atherosclerosis...
  64. ncbi Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation
    W H Wilson Tang
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J3 4, Cleveland, OH 44195, USA
    Arterioscler Thromb Vasc Biol 30:634-40. 2010
    ..Herein, we examine the relationship between different degrees of subclinical myocardial necrosis and long-term adverse clinical outcomes within a stable cardiac patient population with essentially normal renal function...
  65. ncbi Strategies for the development of new PPAR agonists in diabetes
    Matthew A Cavender
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Eur J Cardiovasc Prev Rehabil 17:S32-7. 2010
    ..Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed...
  66. ncbi Peripheral arterial disease and progression of coronary atherosclerosis
    Ayman A Hussein
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA
    J Am Coll Cardiol 57:1220-5. 2011
    ..The purpose of this analysis was to characterize the progression of coronary atherosclerosis in patients with concomitant peripheral arterial disease (PAD)...
  67. ncbi Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine and Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio, USA
    JAMA 299:1547-60. 2008
    ..Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease...
  68. ncbi Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk
    Tamali Bhattacharyya
    Department of Cell Biology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    JAMA 299:1265-76. 2008
    ..The relationship between PON1 genotypes and functional activity with systemic measures of oxidative stress and cardiovascular disease (CVD) risk in humans has not been systematically investigated...
  69. ncbi Formation of dysfunctional high-density lipoprotein by myeloperoxidase
    Stephen J Nicholls
    Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Trends Cardiovasc Med 15:212-9. 2005
    ..Myeloperoxidase-mediated loss of the atheroprotective functional properties of HDL may thus provide a novel mechanism linking inflammation and oxidative stress to the pathogenesis of atherosclerosis...
  70. ncbi Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus
    John M Galla
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Expert Rev Cardiovasc Ther 7:85-93. 2009
    ..More recently, arterial wall imaging has helped characterize the natural history of coronary atherosclerosis in diabetes, the impact of associated risk factors and the influence of medical therapies...
  71. ncbi Application of intravascular ultrasound in anti-atherosclerotic drug development
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Nat Rev Drug Discov 5:485-92. 2006
    ....
  72. ncbi Coronary angiography for follow-up of heart transplant recipients: insights from TIMI frame count and TIMI myocardial perfusion grade
    Nezihi Baris
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Heart Lung Transplant 26:593-7. 2007
    ....
  73. ncbi Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    JAMA 298:1180-8. 2007
    ..Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence is mixed regarding the influence of medications of this class on cardiovascular outcomes...
  74. ncbi Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit?
    Kiyoko Uno
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Mail Code JJ 65, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Atheroscler Rep 12:14-9. 2010
    ..As a result, a favorable influence on the ratio of atherogenic and protective lipid species is likely to have the most profound impact on cardiovascular risk in statin-treated individuals...
  75. ncbi [Assessment of progression and regression of coronary atherosclerosis by intravascular ultrasound. A new paradigm shift?]
    Stephen J Nicholls
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Rev Esp Cardiol 59:57-66. 2006
    ..This heralds a paradigm shift that emphasizes plaque regression as a potential target in the development of preventive strategies...
  76. ncbi Myeloperoxidase and cardiovascular disease
    Stephen J Nicholls
    Department of Cardiovascular Medicine and Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arterioscler Thromb Vasc Biol 25:1102-11. 2005
    ..As a result, MPO and its downstream inflammatory pathways represent attractive targets for both prognostication and therapeutic intervention in the prophylaxis of atherosclerotic cardiovascular disease...
  77. ncbi Biomarkers of inflammation and oxidative stress in atherosclerosis
    Kiyoko Uno
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Biomark Med 4:361-73. 2010
    ..The discovery of these pathological mediators and their potential translation to the clinical arena will be reviewed...
  78. ncbi Brain natriuretic peptides as biomarkers for atherosclerosis
    Kellan E Ashley
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Prev Cardiol 11:172-6. 2008
    ..Given its prognostic utility in heart failure and acute coronary syndrome, brain natriuretic peptide (BNP) and its amino-terminal fragment have received interest as possible biomarkers for CHD...
  79. ncbi Recent trends in coronary intravascular ultrasound: tracking atherosclerosis, pursuit of vulnerable plaques, and beyond
    Ilke Sipahi
    Intravascular Ultrasound Core Laboratory, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Nucl Cardiol 13:91-6. 2006
    ..Whether radiofrequency signal analysis or elastography will become clinically useful tools for detecting vulnerable plaques remains an unanswered, burning question...
  80. ncbi Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits
    Stephen J Nicholls
    The Heart Research Institute, Sydney, Australia
    Arterioscler Thromb Vasc Biol 25:2416-21. 2005
    ..CONCLUSIONS: Infusing small amounts of HDL rapidly reduces lesion size and is comparable to atorvastatin in promoting a stable plaque phenotype...
  81. ncbi Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden
    Christie M Ballantyne
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Tex 77030, USA
    Circulation 117:2458-66. 2008
    ..Intravascular ultrasound showed atheroma volume regression in a single coronary artery with <50% angiographic luminal narrowing...
  82. ncbi Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits
    Stephen J Nicholls
    Heart Research Institute, Sydney, Australia
    Circulation 111:1543-50. 2005
    ..CONCLUSIONS: Infusion of rHDL, apoA-I, and phospholipid-SUVs inhibits the early pro-oxidant and proinflammatory changes induced by a periarterial collar in normocholesterolemic rabbits...
  83. ncbi High-density lipoproteins: an emerging target in the prevention of cardiovascular disease
    Belinda A Cutri
    The Heart Research Institute, Camperdown, Sydney, NSW 2050, Australia
    Cell Res 16:799-808. 2006
    ..This paper will review how the promotion of the functional properties of HDL inhibits the formation of atherosclerotic plaque and stabilises lesions in patients with established disease...
  84. ncbi Statins targeting inflammation by lowering low-density lipoprotein?
    E Murat Tuzcu
    J Am Coll Cardiol 49:2010-2. 2007
  85. ncbi Studying coronary plaque regression with IVUS
    Stephen J Nicholls
    J Interv Cardiol 19:345. 2006
  86. ncbi The role of myeloperoxidase in the pathogenesis of coronary artery disease
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Jpn J Infect Dis 57:S21-2. 2004
    ..In addition, modified HDL appears to be a strong predictor of clinical risk. These features highlight MPO and its products as potential predictive markers and targets in atheroprotection...
  87. ncbi High-density lipoproteins as therapeutic targets
    Stephen J Nicholls
    The Heart Research Institute, Sydney, Australia
    Curr Opin Lipidol 16:345-9. 2005
    ....
  88. ncbi Intravascular ultrasound in the current percutaneous coronary intervention era
    Ilke Sipahi
    Intravascular Ultrasound Core Laboratory, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cardiol Clin 24:163-73, v. 2006
    ..It remains unknown whether the use of emerging IVUS-based technologies such as elastography or spectral analysis is feasible for identification of vulnerable plaques...
  89. ncbi Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function
    Stephen J Nicholls
    The Heart Research Institute, Sydney, Australia
    J Am Coll Cardiol 48:715-20. 2006
    ..In contrast, the anti-inflammatory activity of HDL improves after consumption of polyunsaturated fat. These findings highlight novel mechanisms by which different dietary fatty acids may influence key atherogenic processes...
  90. ncbi Quantification of 3-nitrotyrosine levels using a benchtop ion trap mass spectrometry method
    Stephen J Nicholls
    Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, Department of Cell Biology, Cleveland, OH 44195, USA
    Methods Enzymol 396:245-66. 2005
    ....
  91. ncbi Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo
    Rajesh Puranik
    The Heart Research Institute, Lipid Research Group 145, Missenden Road, Sydney, NSW 2050, Australia
    Atherosclerosis 196:240-7. 2008
    ..These findings have potential implications for treating acute vascular inflammation in conditions such as acute coronary and stroke syndromes...
  92. ncbi Exposing the complexity of HDL
    Stephen J Nicholls
    Cleve Clin J Med 74:709-10, 712. 2007
  93. ncbi Strategies to promote HDL-C: an emerging therapeutic target
    Stephen J Nicholls
    Eur Heart J 26:853-5. 2005